American Bio Medica Corporation engages in develop

American Bio Medica Corporation engages in developing, manufacturing, and marketing point of collection testing (POCT) products for drugs of abuse (DOA). The company provides urine-based POCT products that test various drugs, including amphetamines, barbiturates, benzodiazepines, buprenorphine, cocaine, MDMA, methadone, methamphetamines, opiates, oxycodone, PCP, propoxyphene, THC, and tricyclic antidepressants. Its urine-based POCT products comprise Rapid Drug Screen to detect the presence or absence of 2 to 10 DOA; Rapid ONE for testing the presence or absence of a single DOA; RDS InCup, which detects the presence or absence of 2 to 12 DOA; Rapid TOX that detects the presence or absence of 2 to 10 DOA; and Rapid TOX Cup II for detecting the presence or absence of 2 to 14 DOA. The company also offers oral fluid based POCT products, which test for amphetamines, barbiturates, benzodiazepines, cocaine, MDMA, methadone, methamphetamines, opiates, PCP, propoxyphene, and THC drugs. Its oral fluid based POCT products include OralStat to detect DOA in oral fluids; and Rapid STAT that enhances drug recovery and provides a transport container for confirmation of positive test results. In addition, the company distributes Rapid Reader unit that uses a camera to capture a picture of the results on an ABMC POCT product; and various POCT products to detect the presence or absence of adulterants and alcohol, as well as offers bulk strip contract manufacturing services to various non-affiliated POCT diagnostic companies. American Bio Medica Corporation sells its products through direct sales channels and distributors in North America, Europe, Asia/Pacific Rim, South America, and Africa. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was founded in 1986 and is based in Kinderhook, New York.